Pterostilbene
Catalog No: CFN90397
Pterostilbene acts as a peroxisome proliferator-activated receptor alpha (PPARalpha) agonist, it has been implicated in anticarcinogenesis, antioxidant, modulation of neurological disease, anti-inflammation, attenuation of vascular disease, and amelioration of diabetes. Pterostilbene downregulates inflammatory iNOS and COX-2 gene expression in macrophages by inhibiting the activation of NFkappaB by interfering with the activation of PI3K/Akt/IKK and MAPK.
Pterostilbene may protect HUVECs against oxLDL-induced apoptosis by downregulating LOX-1-mediated activation through a pathway involving oxidative stress, p53, mitochondria, cytochrome c and caspase protease.
Puerarin
Catalog No: CFN99169
Puerarin is a 5-HT2C receptor and benzodiazepine site antagonist, it exerts a regulatory effect on lipid accumulation by decreasing lipogenesis in hepatocytes, it may have therapeutic benefits in the treatment of fatty liver and lipid-related metabolic disorders, it also may act as an intracellular ROS scavenger, and its antioxidant properties may protect against Abeta25-35-induced cell injury,and apoptosis and could also promote the survival of PC12 cells.
Pueroside B
Catalog No: CFN95141
Pueroside B may can treat coronary heart disease, it can interact with two or more targets[peroxisome proliferator activated receptor γ (PPAR-γ), angiotensin-converting enzyme (ACE), hydroxymethylglutaryl coenzyme A receptor (HMGR), cyclooxygenase-2 (COX2), and thrombin].
